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Adverse effects of lead on human health
have been recognized for centuries. Neverthe-
less, current public health measures require a
greater understanding of the pathobiology of
chronic low level exposure (1-3). Such consid-
erations are related to the question of what
level of lead intake is harmful and why
specific clinical manifestations of lead poison-
ing are encountered under particular circum-
stances. The recognition of factors, both
synergistic and antagonistic, which influence
the toxicity of lead is essential for adequate
understanding of the effects of environmental
lead on human health. The immense body of
literature already written about lead contains
many clues to and impressions of such factors,
both adverse and beneficial, modifying the
toxicity of lead. This brief review will discuss
anumber of such factors. Few of these have as
yet been subjected to rigorous experimental
confirmation. A consideration of antagonisms
and synergisms is based on certain assump-
tions with regard to the metabolism of lead;
that is, the daily intake and excretion of lead
as well as the movement of lead between
various tissues and effects on cells and
subcellular organelles.
Metabolism of Lead
The principle route of entry of lead into
the body is oral. Net absorption of lead by
the gastro-intestinal tract is about 5 to 15 per
cent; the rest is excreted in the feces. Even
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inhaled lead particles with an average
diameter above 0.5 ,u are cleared by cil-
iary action of respiratory epithelial cells and
swallowed into the gastro-intestinal tract. The
daily intake of lead by adults probably varies
from 0.10 mg/day to more than 2 mg but
averagesbetween 200 and 500,ugperday(4-5).
Most information about lead metabolism is
related to levels of intake and excretion;
we know even less about howlead movesabout
in the body or how it is handled at the
cellular level. It is here that more knowledge
is very much needed. Inside the body lead
must exist in two forms: a diffusible or
mobile form and a non-diffusible or fixed
form. Lead must be in a diffusible form in
tissues which transport it from one part of the
body to another as in red blood cells and
plasma, and in organs where lead is trans-
ported across cell membranes as in the liver
and kidneys. Diffusible lead is sometimes
equated with "biologically active" lead but
this term may be more appropriately reserved
for forms of lead which bind to membranes,
enzymes, or other proteins.
Most lead in blood is fixed to the red blood
cell in a non-diffusible fraction but it is
thought that approximately 5% is chelated in
the plasma to small diffusible ligands (6). The
nature of these microligands is not known but
may be small organic acids or peptides.
The liver is an important organ in the
metabolism of lead. From experimental
studies in dogs and rats it has been learned
that lead is excreted from the liver mainly in
bile (7, 8). A portion of ingested lead may be
absorbed from the upper gastro-intestinal
tract, transported across liver cells and ex-
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system. The role of the entero-hepatic circu-
lation in lead metabolism has not been
quantitatively studied in man.
Lead is excreted by the kidney in two
ways; by glomerular filtration and trans-
tubular flow. Teisinger (9) has shown that
urine lead levels correlate with blood lead
levels when blood lead is in the normal range
and Selander and Cramer (10) have shown a
similar correlation for elevated blood lead
levels. These correlations, however, are only
statistically valid relationships, true for a large
number of samples, but an individual urine
sample cannot serve in predicting blood lead
levels unless, of course, the urine lead level is
very high, ie. over 150 ,ug/day. In other organs
of the body, lead is nearly completely
non-diffusible or bound lead. Over 90% of the
total amount of lead in the body is in bone.
The organs with the least concentrations are
skeletal or cardiac muscle.
There has long been debate whether lead
content of various tissues increases with age.
Early studies suggested not, but recent reports
which are conducted more precisely show
that lead does in fact, accumulate in the
body with age, especially in bone. Soft tissue
lead concentrations, particularly after the
second decade, are realtively constant so that
the lead which is retained is for the most part
fixed lead or non-diffusible lead.
Total body burden of lead has been
variously estimated to range from 150 to 400
or more mg for average adults in the Western
World. In the recent study by Barry and
Mossman (11), lead content of tissues ob-
tained at autopsy show a mean lead body
burden of 175 mg for a 70 kg male without
history of abnormal exposure to lead. Body
burden of lead may be less than 2 mg for
children under 10 years of age to over 200 mg
for persons in their eighth and ninth decades.
Hair may be an easily accessible tissue from
which to obtain estimates of body stores of
lead and other tracemetals, but caution is
suggested in this estimation (12).
Toxic Effects of Lead
The most prominent signs and symptoms
of lead intoxication may be related to three
organ systems: the central nervous system,
the hematopoietic system and the kidney.
The clinical signs and diagnosis of lead
toxicity has been reviewed in detail elsewhere
but for the purpose of this review it is
important to recognize that in most instances
the onset of lead poisoning is a slowly
progressive process accompanied by a variable
continuum of biochemical and clinical mani-
festations.
These effects may be divided into several
categories, metabolic, functional and
histological. The anemia of lead poisoning
results from impaired heme synthesis and
shortened red blood cell life span. Renal
effects include tubular dysfunction and per-
haps a form of chronic nephropathy, and
central nervous system effects extend from
non-specific behavioral abnormalities to
encephalopathy, coma and death (13). it is
difficult, therefore, to establish a definitive
clinical symptom or value for one laboratory
test above which a person has lead poisoning.
Instead, the effects form a spectrum from no
effect to definite, clear-cut toxicity.
Blood lead values are probably the most
useful parameter to establish whether or not
onehas excessive level of lead absorption.
Among lead industry workers the accept-
able upper limit of blood lead concentration
is set at 70 jig per 100 ml (10) but many re-
ports claim that 60 ,ug per 100 ml is the upper
limit that should be tolerated in persons with-
out a known source of excessive exposure to
lead. In a recent review of blood lead values in
various segments of the population, par-
ticularly children, it has been emphasized that
40 ,ug per 100 ml. should be the maximum
upper limit of "normal" (1).
Factors Influencing Susceptibility
Whether exposure to a particular dosage of
lead results in overt clinical toxicity or not
may depend on a number of factors both
constitutional and environmental which either
enhance or reduce susceptibility to the toxic
effects of lead. A number of such factors are:
Age
Season of the Year
Calcium, Phosphorus
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Dietary Protein
Vitamin D
Ascorbic Acid
Nicotinic Acid
Alcohol
Other Metals
Co-existent Disease
Intracellular Complexing of Lead (inclusion
bodies)
Age: Acute lead poisoning is most common
in children between the ages of 2 and 5 years
(14-16). Blood lead levels above 40 ,g/100 ml
in children may be associated with non-
specific clinical effects sometimes referred to
as subclinical lead toxicity whereas recog-
nizable symptoms of lead toxicity in adults
are uncommon with blood lead levels below
60 ,g/100 ml. Persons with continued occu-
pational exposure to lead may have blood
levels of 80 to lOO1ig/100 ml with few or no
overt symptoms whereas a young child with
this level of blood lead may already have
convulsions and coma. There are many
reasons why the young might be expected to
be more susceptible to lead. Some of these
have been reviewed by Hardy (17) and
include the greater vulnerability of young
growing tissue and greater variation in gastro-
intestinal acidity or alkalinity to include pH
ranges that may be more likely to dissolve and
hence, increase absorption of lead. Also, shifts
of lead into and out of the growing bone of a
child may influence biologic effects. Whether
comparable doses of lead based on body
weight will produce similar symptoms in
children and adults is difficult to answer.
Children with acute lead intoxication develop
lead encephalopathy but encephalopathy in
adults is rare except as the result of a very
large exposure to lead vapors or organic forms
of lead. Dose-response relationships to large
amounts of lead in humans are not docu-
mented well enough to answer this question.
Also, the greater incidence of lead encephalo-
pathy in the child may reflect inherent sensi-
tivity of the nervous system of the child to
lead. Alternatively, the adult may have a
greater capacity to store lead in an inactive
form in bone. On the other hand, Hardy (17)
has suggested that the worker in a lead indus-
try may be more vulnerable to clinical lead
toxicity following a particular dose of lead at
any time because of the likelihood of a high
level of stored lead or non-diffusible lead in
such persons.
Seasonal Variation: Clinical lead toxicity is
more common among children in summer
months. Also, Kehoe's data (5) suggest that
urinary lead excretion in a person voluntarily
ingesting supplemental lead is greater in the
summer. It would seem, therefore, that this
phenomenon must result from some seasonal
metabolic difference. Two explanations cited
by Baetjer (18) include increased vitamin D
formation from the sun's ultraviolet irra-
diation and increased environmental tem-
perature. This latter notion is supported by
experimental studies showing that lead
poisoned rabbits subjected to 370C die in
about 4 days, whereas lead poisoned rabbits
kept at room temperature survive. Mice
exposed to high temperature and injected
intraperitoneally with lead nitrite have a more
rapid and higher mortality rate than similarly
injected mice kept at room temperature. The
added burden of dehydration further lessens
the survival of lead injected mice (18)
although it is unlikely that dehydration is
clinically relevant in lead poisoned children. It
has been suggested that seasonal metabolic
cycles might explain not only increased
susceptibility to infectious disease but may
influence nutritional and metabolic abnor-
malities (Horton, R.J.M., Personal communi-
cation). These ideas have been reviewed by
Sargent and Sargent (19) but have not been
related to the problems of lead toxicity.
Calcium and Phosphorus: The absorption
of lead from the gastro-intestinal tract as well
as the partitioning of lead in various body
compartments appears to be regulated by the
same physiological mechanisms which control
the metabolism of calcium and phosphorus.
Early studies summarized in papers by
Lederer and Bing (20) and Shields and
Mitchell (21) show that absorption of lead
from the gastro-intestinal tract is impaired by
amounts of dietary calcium and phosphorus
above certain low limits. The drinking of large
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prophylaxis to lead poisoning but the effec-
tiveness of this custom has been questioned
(22). However, Kostial and coworkers (23)
have shown that calcium and phosphate
additives to cow's milk reduce body burden
of lead in newbom rats. Greater retention of
trace amounts of dietary lead203 occurred in
5-7 day old rats fed cow's milk only,
compared to cow's milk supplemented with
calcium and phosphate.
Shields and Mitchell (21) conclude that low
dietary calcium, phosphorus or both induce a
higher retention of lead in the body in
comparison with diets containing higher levels
of these minerals. Attempts to partition the
increase in retained lead between bone and
soft tissues were limited to a few experiments.
Six and Goyer (24) have shown that low
dietary calcium greatly enhances the severity
of anemia and biochemical parameters of lead
poisoning including blood lead levels and
urinary d-ALA excretion and aminoaciduria
in rats given the same aount of lead in their
drinking water (200 Mg/ml).
Iron Deficiency: Children with lead poison-
ing often have iron deficiency anemia and
either lead poisoning or iron deficiency results
in a microcytic anemia. A synergism between
the two conditions has been suspected. The
tendency for children to have pica, a factor in
childhood lead poisoning, may be one level of
interaction between these two conditions.
Experimental iron deficiency, however, does
result in greater tissue concentrations of lead
and toxicity in rats given subtoxic levels of
lead than occurs in control rats (25).
The mechanisms by which calcium and iron
deficiencies enhance susceptibility to lead
toxicity appear different as shown in Table 1.
In control animals without added lead, lower-
ing the dietary levels of calcium or iron results
in significantly increased levels of lead in
bone. There is no elevation of soft tissue lead
on the low iron diet and a slight elevation of
soft tissue lead on the low calcium diet. This
is without added lead. When lead is added to
the drinking water at the level of 200 ,ug per
ml, there is an increase in bone lead on a
nutritionally adequate diet. Soft tissue lead is
also increased. On a low iron diet, bone lead
approximately triples in content but soft
tissue lead remains approximately the same as
on the nutritionally adequate diet.
Table 1. Comparison of Tissue Concentrations
(ug/g wet tissue) of Lead in Rats Fed Diets Deficient in
Calcium (LCa) and Iron (LFe) and Nutritionally Adequate
Diets (NCa, NFe). Data is From Six and Goyer (24, 25)
DIET BONE Pb KIDNEY Pb
No Pb
NCa, NFe 2.2 ± 1.0 2.6 ± 1.2
LFe 10.6 3.0 1.9 0.4
LCa 9.7 2.2 4.4 0.6
200,ugPb/ml H20
NCa,NFe 74 12 22 4.3
LFe 225 15 28.7 4.8
LCa 202 22 691 203
With the low calcium diet, bone lead is
approximately equal to that found in rats fed
the low iron diet. However, soft tissue lead is
approximately 25 to 30 times that seen on
either the nutritionally adequate or iron
deficient diet. The changes in renal lead
content on the low calcium diet are accom-
panied by indicators of renal dysfunction,
such as elevated aminoaciduria and increased
renal size. Therefore, low dietary calcium
greatly alters the partitioning of lead from the
fixed lead in bone to the diffusible lead in
soft tissue. In general, the pathological effects
of lead are associated with elevated soft tissue
levels but partitioning of lead may be influ-
enced by deficiencies of particular nutrients.
Protein: Dietary protein may influence lead
intoxication. An early paper on this subject is
that of Baernstein and Grand (26). Young rats
were fed lead chloride (1.5%) in diets contain-
ing 6, 13 or 20% protein. Decrease in weight
gain and mortality diminished on diets with
higher protein levels. Addition of cystine or
methionine to the 6% casein diet decreased
mortality and improved weight gain in
the lead-fed as well as control rats.
More recently Gontzea and coworkers (27)
observed that pair-fed rats on a 9% protein
diet showed greater susceptibility to lead
intoxication as compared to rats fed an 18%
casein diet as judged by the lead content of
liver, kidney and blood.
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poisoning in the experimental animal. Lead
concentration in blood and bones is greater in
animals receiving this vitamin than in those
not receiving this addition (28). Presumably,
vitamin D enhances gastrointestinal absorp-
tion of lead as it does that of calcium.
Whether increased bone deposition of lead
during vitamin D administration reflects a
specific effect on bone metabolism or merely
reflects increased blood levels of lead is not
clear.
Ascorbic Acid: The addition of large
amounts of ascorbic acid to the diet of
industrial workers was suggested as a means of
alleviating symptoms of lead intoxication
such as basophilic stippling of the
erythrocyte (29). Pillemer and coworkers (30)
found that lead poisoned guinea pigs on a
scorbutic diet developed neurological
symptoms more readily than did lead
poisoned animals fed ascorbic acid adequate
diets. Otherinvestigators, however, have found
ascorbic acid to be without effect in lead
toxicity (31, 32).
Nicotinic Acid: A number of experimental
studies suggest that nicotinic acid synthesis
from tryptophan is impaired in experimental
lead poisoning. (33-36) However, using
tryptophan load tests, Tenconi and Acocella
(37) concluded that lead intoxication in rats
did not cause changes in tryptophan
metabolism similar to that seen in pyridoxine
deficient states.
Alcohol: It has been suggested that persons
who are alcoholic are more susceptible to the
toxic effects of lead (38). Little is known
about the basis for the apparent synergism
between alcohol and lead, particularly at the
molecular level. If the cellular pathology of
lead and alcohol are compared, similarities are
observed. Each alone can produce
mitochondrial injury. In vitro studies of
mitrochondria from ethanol-treated rats show
decreased oxidative capacity and increased
membrane permeability (39). Another possi-
ble mechanism for synergism between lead
and alcohol is through the introduction of
nutritional deficiencies by alcoholism which
enhance the toxicity of lead. These de-
ficiencies include calcium, protein and
vitamins which have alreay been commented
upon.
Other metals: It might be expected that the
metabolism of different heavy metals is
similar enough to have overlapping or similar
toxic effects. Several of the heavy metals bind
in vivo to red blood cells. However, the
attachment of lead to the red blood cell
membrane is not influenced (in vitro) by the
presence of other heavy metals including
cadmium, mercury, zinc and aluminum which
suggests that lead may be metabolized inde-
pendent of other metals (40). It has been
recently learned that cadmium is elevated
along with lead in the blood of children with
suspected lead poisoning and possible toxic
synergism between these metals is being
explored clinically (41). In addition synergism
between lead and cadmium has recently been
shown to cause teratogenic effects in
experimental animals (42).
Influence of co-existent disease: Pre-
existent disease of major organ systems may
enhance the vulnerability of affected persons
to the toxic effects of lead but documen-
tation of this type of synergism is limited. A
report from Europe points out the increased
susceptibility of persons with hemoglobin
anomalies, such as hemoglobin S and C
diseases and thalassemia, to toxins like lead
which affect red blood cell metabolism (43).
Carriers of such defects must be recognized
and protected from lead exposure.
Glucose-6-phosphate dehydrogenase
deficient individuals may also show increased
susceptibility to lead and should be identified
by a screening test to avoid employment in a
lead industry (44).
The kidney has a key role in lead metabo-
lism and chronic renal disease from any cause
must reduce the lead excretory capacity of an
individual and studies in rats suggest that the
immature kidney is more susceptible than the
adult kidney and reduced renal excretory
function as occurs in unilateral nephrectomy
enhances the toxicity of lead (45).
Intracellular complexing of lead (inclusion
bodies): Partitioning of lead between sub-
cellular organelles may influence the toxic
October 1972 77potential of a particular dose of lead. Lead
has a strong affinity for mitochondrial mem-
branes and mitochondria isolated from liver
and kidneys of lead-intoxicated animals have
impaired respiratory and phosphorylative
abilities. The in vivo appearance of
mitochondria in renal tubular cells of lead
poisoned experimental animals and humans
shows altered ultrastructure. Measurement of
lead content of cell organelles, however, has
demonstrated that the major fraction of lead
in renal tubular lining cells is in the nucleus
bound in a lead-protein complex in the form
of an intranuclear inclusion body (46). These
bodies are seen by microscopy of liver or
renal tubular cells from lead poisoned sub-
jects. The ultrastructure of a typical inclusion
body in the nucleus of a renal tubular lining
cell of a lead-intoxicated rat is shown in Fig.
1. The lead content of these bodies has been
confirmed by autoradiography (47), electron
probe microanalysis (48) and direct measure-
ment following isolation and purification by
OrV
differential centrifugation (46, 49). It is
suggested that the binding of lead that occurs
in the inclusion body serves as an adaptive or
protective mechanism during transcellular
transport of lead (50). In the course of
excretion of lead from capillaries to bile by
hepatic cells, or by transtubular flow in renal
tubular lining cells a portion of the lead enters
the nucleus where it becomes bound into a
lead-protein complex and is no longer diffusi-
ble. This mechanism has the effect of main-
taining a relatively low cytoplasmic concen-
tration of lead, and, therefore, reducing the
toxic effects of lead on sensitive cellular
functions, such as mitochondrial respiration
and protein synthesis.
Indirect support for this hypothesis is
found in experimental studies of the relation-
ship of the formation of intranuclear inclu-
sion bodies and other renal effects of lead.
Intranuclear inclusion bodies are observed at a
lower dose levels of lead than any other renal
effect of lead; in fact, at a lower dose of lead
5-, 92` I.
4
T
FIGURE 1. Ihtranuclear inclusion body of renal tubular lining cell consisting of a dense central core with
fibrillary margins. X20,000
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symptoms of lead toxicity (46, 50).
Summary
There is considerable variation in human
susceptibility to lead toxicity and a number
of factors have been identified as synergistic
and antagonistic. The influence of deficiencies
of dietary calcium and iron has been studied
experimentally and found to increase soft
tissue retention of a particular dose of lead.
Synergism with other toxic metals, particu-
larly cadmium, has been suggested but this
relationship needs further study.
Genetic factors, such as hemoglobin S and
C, and glucose-6-phosphate dehydrogenase
deficiencies are also suspected of increasing
susceptibility to lead but large scale clinical
support of this relationship is not yet
available.
Renal disease decreases excretion oflead,
thus enhancing body stores and toxicity.
Also of importance are intrinsic metabolic
factors which influence subcellular par-
titioning of lead. The binding of lead as a
non-diffusible protein complex in the form of
intranuclear inclusion bodies in liver and
kidney may function as an intracellular
detoxifying mechanism as well as facilitate
renal excretion of lead.
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